Alcoholic Hepatitis : The Rising Epidemic - 30/03/23

Doi : 10.1016/j.mcna.2022.12.005

Pranav Penninti, DO ^a, Ayooluwatomiwa D. Adekunle, MD, MPH ^b, Ashwani K. Singal, MD, MS ^c,^d,^e,^⁎
^a Division of Gastroenterology and Hepatology, University of Texas Health San Antonio, TX, USA
^b Department of Medicine, University of Kentucky, KY, USA
^c University of South Dakota Sanford School of Medicine, Sioux Falls, SD, USA
^d Avera Transplant Institute and University Hospital, Avera McKennan University Hospital
^e VA Medical Center, Sioux Falls, SD 57105, USA

^∗Corresponding author. University of South Dakota Sanford School of Medicine, Sioux Falls, SD, USAUniversity of South Dakota Sanford School of MedicineSioux FallsSDUSA

Résumé

Alcoholic hepatitis (AH) is a unique clinical syndrome on the spectrum of alcohol-associated liver disease (ALD). It constitutes a rising epidemic with increasing incidence and major public health implications. In severe AH, 30-day mortality approaches 30%, yet therapeutic options remain limited. Survival benefit from corticosteroids, the mainstay of medical treatment, is short-lived. Among corticosteroid nonresponders, the use of early liver transplantation is heterogeneous across centers and remains limited by significant barriers. Long-term prognosis is largely dictated by abstinence; however, comorbid alcohol use disorder remains undertreated. Efforts to address these challenges are required to curb the AH epidemic.

Le texte complet de cet article est disponible en PDF.

Keywords : Alcoholic hepatitis, Alcohol use disorder, Alcohol-associated liver disease, AH, AUD, ALD